悦安新材（688786）：Q3业绩环比增长，期待新产能贡献业绩增量

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [5][17]. Core Insights - The company achieved a revenue of 321 million yuan in the first three quarters of 2025, representing a year-over-year increase of 3.2%. In Q3 alone, revenue reached 117 million yuan, up 10.8% year-over-year and 9.6% quarter-over-quarter [1][2]. - The net profit attributable to the parent company for the first three quarters was 61 million yuan, a year-over-year increase of 9%. In Q3, net profit was 23 million yuan, reflecting a year-over-year growth of 19.3% and a quarter-over-quarter increase of 10.8% [1][2]. - The company is in the process of ramping up production capacity for its carbonyl iron powder project, which is expected to double its capacity from 5,500 tons to 11,500 tons. This new capacity is anticipated to contribute positively to the company's performance as it focuses on high-end product optimization [3][4]. Financial Performance Summary - For Q3 2025, the gross margin was 40.6%, showing a quarter-over-quarter increase of 0.49 percentage points. The net profit margin for Q3 was 19.79%, up 1.47 percentage points from the previous quarter [2]. - The company forecasts net profits of 80 million yuan, 130 million yuan, and 160 million yuan for the years 2025, 2026, and 2027, respectively, corresponding to price-to-earnings ratios of 53, 33, and 26 times [3][4]. Capacity Expansion and Future Outlook - The company’s IPO-funded project for carbonyl iron powder is expected to reach full production capacity by the end of Q3 2023, with gradual capacity release based on market demand. This expansion is projected to alleviate production bottlenecks and enhance profitability through economies of scale [3][4]. - The company is also developing a new process at its Ningxia base, which is expected to further open growth opportunities. The first phase of the carbonyl iron powder demonstration line is anticipated to enter trial production in 2025 [3].